How the biotech capital markets are faring in the time of Covid-19

“The second quarter [of 2020] turned out to be the busiest quarter for biotech equity to date, and just two weeks into the third quarter, the IPO market is firing on all cylinders. The recent uptick in activity following the Covid-19 pandemic has brought about some interesting trends during the 2020 IPO frenzy, that we expect to continue throughout the second half of 2020 and beyond.”

Leave a comment

Your email address will not be published. Required fields are marked *